For people with type 2 diabetes, combining a GLP-1 with an SGLT2 inhibitor can offer complementary benefits for weight, blood sugar, heart health, and kidney protection
In the FLOW trial [see Clinical Studies (14.3)] in patients with type 2 diabetes mellitus and chronic kidney disease, safety data collection was limited to serious adverse events and selected predefined categories of adverse events regardless of seriousness
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for chronic weight management in adults and adolescents with obesity
Instead, theyre made from herbal blends or vitamins with no clinical evidence backing their effectiveness for weight loss or metabolic health
Based on the clinical trial population and the medications mechanism, individuals who may benefit most from retatrutide once it becomes available include: Adults with a BMI of 30 or greater (obesity) Adults with a BMI of 27 or greater who have weight-related conditions such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea Individuals who have not achieved adequate results with semaglutide or tirzepatide Patients seeking greater weight loss than what current medications provide Individuals with metabolic dysfunction-associated steatohepatitis (MASH) given the glucagon receptors role in liver fat metabolism Retatrutide may not be appropriate for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disorders, or a history of pancreatitis
